Metastatic Pancreatic Ductal Adenocarcinoma research hub
7 indexed studies · 5 currently recruiting
- recruitingPHASE2, PHASE3
A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma
This study looks at a new drug, telisotuzumab adizutecan, combined with standard chemotherapy (FOLFOX) for advanced pancreatic cancer. It compares this combination to the usual treatment to see if it works better and is safe for adults.
United States · Australia · Israel - authorisedPhase II and Phase III (Integrated)
Phase 2/3 Open Label Randomized Study of Telisotuzumab Adizutecan in Combination with FOLFOX Compared to Standard of Care in Subjects with First-Line Metastatic Pancreatic Ductal Adenocarcinoma - AndroMETa-PDAC-288
This clinical trial is testing a new targeted medicine called telisotuzumab adizutecan, combined with chemotherapy, for people with advanced pancreatic cancer. Doctors want to see if this new combination shrinks tumours better and helps people live longer compared with standard chemotherapy treatments currently used on the NHS.
Portugal · Spain · France - recruitingPHASE3
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
This study is looking at a new drug, daraxonrasib, for people with pancreatic cancer that has spread. It compares daraxonrasib alone, or with standard chemotherapy (gemcitabine and nab-paclitaxel), against standard chemotherapy by itself. The aim is to see if the new treatments can help people live longer and stop the cancer from growing.
United States · Australia · Austria - recruitingPHASE3
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
This study is testing a new medicine, atebimetinib, alongside standard chemotherapy for pancreatic cancer that has spread. We want to see if this combination works better and is safe for patients who haven't had treatment before.
United States · Australia · Georgia - recruitingPHASE3
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
This study is for people who have had surgery for pancreatic cancer. We are testing a new drug, daraxonrasib, to see if it can stop the cancer from coming back, compared to just being watched. It's to help see if this new treatment works better.
United States · France · Germany - recruitingPHASE3
Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
This study is testing a new drug called zoldonrasib, combined with standard chemotherapy, for people with pancreatic cancer that has spread. It compares this combination to chemotherapy alone, to see if it helps people live longer or stops the cancer from growing for longer. It focuses on a specific type of cancer gene.
United States · United Kingdom - active not recruitingPHASE3
Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
This study is looking for a new treatment for pancreatic cancer that has spread. It compares a new medicine called RMC-6236 with standard chemotherapy for people whose cancer has already been treated once before. The aim is to see if the new medicine is safer and works better.
United States · France · Germany